Showing 4 posts of 4 posts found.


Lilly’s Emgality smashes all Phase 3 endpoints in migraine sub-population

August 6, 2019
Manufacturing and Production, Research and Development Eli Lilly, Emgality, migraine, pharma

New Phase 3 data have been revealed on Eli Lilly’s Emgality (galcanezumab-gnlm), detailing its success in meeting all of its …


Eli Lilly’s Emgality approved in the US for episodic cluster headache

June 5, 2019
Research and Development, Sales and Marketing Eli Lilly, Emgality, episodic cluster headache, migraine, pharma

Eli Lilly’s Emgality (galcanezumab-gnlm) self-administered injection solution has secured approval in the US for the treatment of episodic cluster headache, …


Eli Lilly’s Emgality shows positive Phase 3 results in treatment of migraine

May 8, 2019
Research and Development Eli Lilly, Emgality, cluster headache, headache, migraine, pharma

Eli Lilly has announced positive results from the Phase 3 EVOLVE-1 and EVOLVE-2 trials looking into Emgality (galcanezumab-gnlm) for the …


Eli Lilly’s Emgality cleared for treatment of migraine in Europe

November 20, 2018
Manufacturing and Production, Sales and Marketing EU, Eli Lilly, Emgality, Europe, migraine, pharma

Eli Lilly’s Emgality (galcanezumab) has secured approval from the European Commission for the prophylaxis of migraine in adult patients who …

Latest content